Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05910268 · ClinicalTrials.gov registry record · NA

Peru Decentralized HIV Care

A NA study of HIV, sponsored by Yale University.

Recruiting
Registry status
NA
Development phase
1,450
Enrollment target
2
Study locations

NCT05910268: Recruiting NA study of HIV, sponsored by Yale University.

NCT05910268 is a NA study of HIV that is actively recruiting participants, run by Yale University. The registered enrollment target is 1,450 participants, above the 435-participant average among 303 other HIV trials with a reported enrollment target (233% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05910268, a NA study of HIV, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
NA
Development phase
1,450 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to understand the processes by which HIV care is decentralized, an evidence-informed strategy to improve retention in HIV care, in Peru. Decentralization of HIV services has not been evaluated using experimental designs and urban decentralization studies of HIV are uncommon, so this study will lend important insights for future decentralization efforts in Peru and other countries.

Primary Outcome

The percentage of diagnosed PWH in treatment in PHC within the district will be used to assess the extent to which decentralized services are adopted and scaled-up in PHCs. Higher percentage indicates more services adopted and scaled-up.

Conditions Studied

Interventions

  • BEHAVIORAL NIATx + ECHO

Study Locations (2)

Connecticut

  • Yale University - New Haven

Other

  • CITBM - Centro de Investigaciones Tecnológicas Biomédicas y Medioambientales - Bellavista

Trial Details

FieldValue
Enrollment Target 1,450 participants
Start Date 2024-04-01
Est. Completion 2028-07-01
Phase NA
Yale University

1,492 total trials

What NCT05910268 shows while recruiting

NCT05910268 is an interventional study that assigns participants to a tested intervention. Its 1,450 participants enrollment target places it among the larger protocols in the corpus, above the 435-participant average among 303 other HIV trials with a reported enrollment target (233% higher).

The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 1 intervention - of which NIATx + ECHO is the first listed.

NCT05910268 reports a single indexed study location in Connecticut, Other.

Frequently Asked Questions

What is clinical trial NCT05910268 about?

NCT05910268 is a clinical study titled "Peru Decentralized HIV Care". The purpose of this study is to understand the processes by which HIV care is decentralized, an evidence-informed strategy to improve retention in HIV care, in Peru. Decentralization of HIV services has not been evaluated using experimental designs and urban decentralization studies of HIV are uncom...

What is the current status of trial NCT05910268?

This trial is currently recruiting. It is a NA study. The enrollment target is 1,450 participants. The study started on 2024-04-01. Estimated completion is 2028-07-01.

What conditions does trial NCT05910268 study?

This clinical trial studies the following conditions: HIV.

What interventions are being tested in trial NCT05910268?

The interventions under investigation include: NIATx + ECHO (BEHAVIORAL).

Who is sponsoring clinical trial NCT05910268?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05910268 being conducted?

This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05910268's enrollment target sits among peer trials

1,450 14th of 303 higher than 290 of 303 other HIV trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04566328 · 1,450 participants · Phase 3

    Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

  • NCT05229341 · 1,450 participants · NA

    Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules

  • NCT06305312 · 1,450 participants · NA

    Community Services Navigation to Advance Health Equity in Breast Cancer Screening

  • NCT06782347 · 1,454 participants · NA

    Activating SilverSneakers Benefits for Seniors With Osteoarthritis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05910268, the US trial registry maintained by the National Library of Medicine. NCT05910268 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.